Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.352 5-летний Импакт фактор: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v30.i4.30
pages 345-386

Tumor Antigen Presentation by Dendritic Cells

Troels R. Petersen
Malaghan Institute of Medical Research, Wellington, New Zealand
Nina Dickgreber
Malaghan Institute of Medical Research, Wellington, New Zealand
Ian F. Hermans
Malaghan Institute of Medical Research, Wellington, New Zealand

Краткое описание

Tumor cells are generally regarded as poor stimulators of naive T cells. In contrast, dendritic cells (DCs) are highly specialized in this function, and are therefore likely to be important intermediaries in the process of stimulating T cell responses to tumors. While providing solid evidence that DCs participate in antitumor immunity has proved difficult, several lines of evidence point in this direction. First, animal models involving bone marrow chimeras have shown that cells of hematopoeitic origin are required to elicit T cell responses to whole-tumor vaccines. Second, compared with other cells of hematopoeitic origin, DCs are particularly well-equipped to cross-present exogenous antigens to CD8+ T cells, a critical function if intermediary cells are involved. Third, tumor-infiltrating DCs purified from tumor samples have the capacity to cross-present tumor antigens in vitro. Finally, priming of anti-tumor T cell responses can be abrogated in new in vivo models in which DCs can be specifically depleted. It is therefore significant that DCs in cancer patients are often kept in an immature or dysfunctional state, thereby preventing stimulation of tumor-specific T cells. This review describes the different steps required for DCs to elicit T cell responses to tumor-associated antigens, and highlights processes that are amenable to intervention as therapy. We conclude that effective anti-tumor activity may be dependent on the ability to re-program DCs resident in the host, perhaps even when transferred autologous DCs generated ex vivo are used as vaccines. In this context, recruiting the activity of cells of the innate immune system to condition host DCs may help elicit more effective T cell-mediated responses.

Articles with similar content:

CD4+ T Cells Orchestrate Both Amplification and Deletion of CD8+T Cells
Critical Reviews™ in Immunology, Vol.18, 1998, issue 6
Enza Piccolella, Loredana Frasca, Cinzia Piazza
CD8+ Memory T Lymphocytes from Bone Marrow— Immune Function and Therapeutic Potential
Critical Reviews™ in Immunology, Vol.27, 2007, issue 6
Xiaoyu Zhang, Donna L. Farber, Scott E. Strome, Aaron H. D. Wood
CD4+ T Cells in Adoptive Immunotherapy and the Indirect Mechanism of Tumor Rejection
Critical Reviews™ in Immunology, Vol.20, 2000, issue 1
Liaomin Peng, David E. Weng, Peter A. Cohen, Suyu Shu, Julian A. Kim, Gregory E. Plautz
Elimination of Virus-Specific Cytotoxic T Cells in the Liver
Critical Reviews™ in Immunology, Vol.22, 2002, issue 1
Gunther Dennert
Dendritic Cell Cross Talk with Innate and Innate-like Effector Cells in Antitumor Immunity: Implications for DC Vaccination
Critical Reviews™ in Immunology, Vol.34, 2014, issue 6
I. Jolanda M. de Vries, Jasper J. P. van Beek, Annette E. Skold, Stanleyson V. Hato, Florian Wimmers